About Gain Therapeutics
Gain Therapeutics (NASDAQ:GANX) is a biotechnology firm at the forefront of developing therapies for rare genetic diseases and neurodegenerative disorders. The company is pioneering a distinctive drug discovery platform that identifies and develops small molecule therapeutics designed to fix protein misfolding, a common pathological mechanism across its target diseases. Gain's pipeline is focused on addressing unmet medical needs in conditions such as Parkinson's disease, Gaucher disease, and GM1 gangliosidosis, aiming to halt or reverse the progress of these debilitating diseases. With a commitment to innovation and improving patient outcomes, Gain Therapeutics is dedicated to becoming a key player in the field of precision medicine, pushing the boundaries of science to deliver transformative treatments.
Snapshot
Operations
Products and/or services of Gain Therapeutics
- Development of structurally targeted allosteric regulators (STARs) for precision medicine in rare genetic diseases.
- Advancement of small molecule therapies for Parkinson's Disease, particularly addressing GBA1 mutation-related cases.
- Research in novel treatments for neuropathic Gaucher disease.
- Exploration of therapy options for diseases caused by misfolded proteins, focusing on protein degradation.
- Collaboration on drug discovery and development projects leveraging their proprietary SEE-Tx platform.
- Investigation into CNS disorder treatments, aiming to cross the blood-brain barrier with innovative approaches.
Gain Therapeutics executive team
- Dr. Khalid Islam Ph.D.Chairman & Founder
- Mr. Gene Mack M.B.A.President, CEO & Director
- Mr. Gianluca FuggettaSenior VP of Finance & Principal Financial Officer
- Dr. Terenzio Ignoni Pharm.D.Senior Vice President of Technical Operations
- Dr. Joanne Taylor Ph.D.Senior Vice President of Research
- Dr. Jonas Hannestad M.D., Ph.D.Chief Medical Officer